SCHEMBL3497732

SCHEMBL3497732

CCOC(=O)C1(CC(N)=O)CCCN(C2CCN(C(=O)OC(C)(C)C)CC2)C1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
CHRM1 P11229 2/20 0.43
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.40
GAA P10253 3/20 0.38
ALOX12 P18054 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK1 P28482 1/20 0.37
NOS3 P29474 1/20 0.37
NOS2 P35228 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494098 0.91 KMT2A (0.55) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3498670 0.88 KMT2A (0.50) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3496509 0.87 KMT2A (0.52) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3494402 0.87 KMT2A (0.49) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3498093 0.87 MEN1 (0.49) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3498031 0.86 L3MBTL1 (0.44) KMT2AMEN1ALDH1A1POLBL3MBTL1
SCHEMBL3497035 0.86 MEN1 (0.48) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3495426 0.85 KMT2A (0.51) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL13312006 0.83 KDM4E (0.53) KMT2AMEN1KDM4EALDH1A1LMNA
Hydrochloric Acid SCHEMBL3498023 0.82 KDM4E (0.53) KMT2AMEN1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC KMT2A 3284/4885MEN1 4260/4885KDM4E 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.